AKAO Hits New Low, INSY Shifts Focus From Opioids, FDA Nod For Theratechnologies

Today's Daily Dose brings you news about Achaogen's corporate restructuring; AVEO Oncology's TIVO-3 trial results; Mirati Therapeutics' near-term catalysts and FDA approval of Theratechnologies' supplemental New Drug Application of Egrifta.

from RTT - Biotech https://ift.tt/2qsYJoQ
via IFTTT